First in the UK: Arthrosamid experience and repeat injections

Bringing Arthrosamid into UK practice

Professor Paul Lee was the first surgeon to bring Arthrosamid into UK clinical practice, according to his published clinical profile. More than 1,200 injections later, his experience spans assessment, injection technique and the conversations that follow when patients return months or years after treatment.

• [1] Professor Lee: joint injections and clinical experience

Looking beyond the first few months

Longer-term follow-up helps answer a practical question: can an improvement last? The published five-year extension study followed people after a single injection and reported sustained improvements in pain, stiffness and function among those assessed. It began with 49 participants; 27 completed the five-year extension.

This was an open-label study without a control group. Its findings support a conversation about lasting symptom relief, while the reduced number followed over time matters when interpreting the results.

• [2] Bliddal et al.: five-year extension study

When a second or third injection is discussed

Professor Lee reports favourable experience with selected repeat injections. A useful consultation starts with the response to the first treatment: what improved, how long the benefit lasted and what has changed since.

Repeat treatment remains a separate evidence question. The October 2025 manufacturer instructions state that repeat injections have not been evaluated in clinical studies. The five-year single-injection study should not be used as a six-year top-up success claim.

• [3] Arthrosamid instructions for use, October 2025

Bring your treatment history into the conversation

The date of earlier injections, previous scans and a description of your best and current function can help the clinician understand your progress. The aim is a plan that responds to your knee today, including whether another injection or a different approach would be more useful.